These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25675384)

  • 1. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.
    Chen KY; Muniyappa R; Abel BS; Mullins KP; Staker P; Brychta RJ; Zhao X; Ring M; Psota TL; Cone RD; Panaro BL; Gottesdiener KM; Van der Ploeg LH; Reitman ML; Skarulis MC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1639-45. PubMed ID: 25675384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.
    Kievit P; Halem H; Marks DL; Dong JZ; Glavas MM; Sinnayah P; Pranger L; Cowley MA; Grove KL; Culler MD
    Diabetes; 2013 Feb; 62(2):490-7. PubMed ID: 23048186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)-Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state.
    Kriketos AD; Thompson HR; Greene H; Hill JO
    Int J Obes Relat Metab Disord; 1999 Aug; 23(8):867-73. PubMed ID: 10490789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
    Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
    Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
    EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
    Falls BA; Zhang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.
    Karhunen L; Franssila-Kallunki A; Rissanen P; Valve R; Kolehmainen M; Rissanen A; Uusitupa M
    Int J Obes Relat Metab Disord; 2000 Dec; 24(12):1567-72. PubMed ID: 11126207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4-10) in humans causes lipolysis in white adipose tissue.
    Wellhöner P; Hörster R; Jacobs F; Sayk F; Lehnert H; Dodt C
    Int J Obes (Lond); 2012 May; 36(5):703-8. PubMed ID: 21629206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.
    Basolo A; Burkholder J; Osgood K; Graham A; Bundrick S; Frankl J; Piaggi P; Thearle MS; Krakoff J
    Metabolism; 2018 Aug; 85():116-125. PubMed ID: 29596853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.
    Kumar KG; Sutton GM; Dong JZ; Roubert P; Plas P; Halem HA; Culler MD; Yang H; Dixit VD; Butler AA
    Peptides; 2009 Oct; 30(10):1892-900. PubMed ID: 19646498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.
    Royalty JE; Konradsen G; Eskerod O; Wulff BS; Hansen BS
    J Clin Pharmacol; 2014 Apr; 54(4):394-404. PubMed ID: 24166760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.
    Redman LM; de Jonge L; Fang X; Gamlin B; Recker D; Greenway FL; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2007 Feb; 92(2):527-31. PubMed ID: 17118998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
    Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
    Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.
    Wynne K; Park AJ; Small CJ; Meeran K; Ghatei MA; Frost GS; Bloom SR
    Int J Obes (Lond); 2006 Dec; 30(12):1729-36. PubMed ID: 16619056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of energy expenditure in the differential weight loss in obese women on low-fat and low-carbohydrate diets.
    Brehm BJ; Spang SE; Lattin BL; Seeley RJ; Daniels SR; D'Alessio DA
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1475-82. PubMed ID: 15598683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A moderate dose of caffeine ingestion does not change energy expenditure but decreases sleep time in physically active males: a double-blind randomized controlled trial.
    Júdice PB; Magalhães JP; Santos DA; Matias CN; Carita AI; Armada-Da-Silva PA; Sardinha LB; Silva AM
    Appl Physiol Nutr Metab; 2013 Jan; 38(1):49-56. PubMed ID: 23368828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects.
    Most J; Goossens GH; Jocken JW; Blaak EE
    Int J Obes (Lond); 2014 May; 38(5):698-706. PubMed ID: 24317366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men.
    Larsen TM; Toubro S; van Baak MA; Gottesdiener KM; Larson P; Saris WH; Astrup A
    Am J Clin Nutr; 2002 Oct; 76(4):780-8. PubMed ID: 12324291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in leptin and peptide YY do not explain the greater-than-predicted decreases in resting energy expenditure after weight loss.
    McNeil J; Schwartz A; Rabasa-Lhoret R; Lavoie JM; Brochu M; Doucet É
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E443-52. PubMed ID: 25494860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.